本文選題：廣東省　切入點：醫(yī)藥制造業(yè)　出處：《廣東藥科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：醫(yī)藥制造業(yè)不單關(guān)系到國家的長遠發(fā)展和人民的生命健康,而且是知識和技術(shù)密集型的高新技術(shù)產(chǎn)業(yè),被世界公認為“朝陽產(chǎn)業(yè)”。在社會民生發(fā)展角度來看,人民的基本健康條件、優(yōu)質(zhì)藥品、追求醫(yī)療保健要求的滿足全有賴于醫(yī)藥制造業(yè)的發(fā)展,進而對我國人民生命安全和身體健康的權(quán)利形成了有力的保障。從社會經(jīng)濟發(fā)展角度來看,醫(yī)藥制造業(yè)不但是醫(yī)藥產(chǎn)業(yè)的主要組成成分,而且是我國經(jīng)濟的有機組成;促進醫(yī)藥制造業(yè)的發(fā)展能夠促進更多人口就業(yè)、進出口貿(mào)易以及基建、技術(shù)投資的增加等,從而促進該地區(qū)乃至該國的經(jīng)濟發(fā)展。因此,研究我國區(qū)域醫(yī)藥制造業(yè)產(chǎn)業(yè)競爭力評價,合理地進行排名,了解廣東省醫(yī)藥制造業(yè)發(fā)展現(xiàn)狀及影響因素,提出合理的發(fā)展建議,這對促進廣東省醫(yī)藥制造業(yè)產(chǎn)業(yè)競爭力的提升有重大的影響作用。本文依據(jù)已有的產(chǎn)業(yè)競爭力、醫(yī)藥制造業(yè)及其競爭力評價方法相關(guān)理論,對廣東省醫(yī)藥制造業(yè)在全國各省市中的競爭力狀況進行了定性、定量研究。首先,對我國及廣東省醫(yī)藥制造業(yè)的產(chǎn)業(yè)發(fā)展現(xiàn)狀進行了分析,內(nèi)容主要包括我國醫(yī)藥制造業(yè)產(chǎn)業(yè)生產(chǎn)經(jīng)營情況、扶持政策及影響及廣東省醫(yī)藥制造業(yè)的產(chǎn)業(yè)發(fā)展?fàn)顩r、特點等。然后,在借鑒已有研究的基礎(chǔ)上,科學(xué)、客觀地構(gòu)建醫(yī)藥制造業(yè)產(chǎn)業(yè)區(qū)域競爭力評價體系。接著,運用因子分析法對2010~2014年五年全國27個省市醫(yī)藥制造業(yè)相關(guān)指標(biāo)的原始數(shù)據(jù)(內(nèi)蒙古、西藏、青海和寧夏)進行實證分析,得出廣東省醫(yī)藥制造業(yè)在全國的競爭力評價結(jié)論。結(jié)論為:通過廣東省同其它省市比較,可得出廣東省醫(yī)藥制造業(yè)綜合競爭力穩(wěn)居前列,具備相對較大優(yōu)勢,但距離絕對優(yōu)勢省市還有較大差距。另外,相關(guān)成分發(fā)展非常不均衡,投入效益及產(chǎn)品創(chuàng)新能力僅處于全國中游水平,是廣東省醫(yī)藥制造業(yè)健康持續(xù)發(fā)展的嚴(yán)重障礙。最后,根據(jù)以上結(jié)論,從政府與企業(yè)兩個角度對廣東省今后醫(yī)藥制造業(yè)的發(fā)展提出了相關(guān)對策和建議。從政府方面,主要包括:大力發(fā)展醫(yī)藥產(chǎn)業(yè)集群規(guī)模,推動區(qū)域協(xié)調(diào)發(fā)展;優(yōu)化產(chǎn)業(yè)扶持方式,增加資本投入渠道;壯大產(chǎn)業(yè)龍頭企業(yè),發(fā)揮區(qū)域藥業(yè)品牌優(yōu)勢;深化對外合作,推動產(chǎn)業(yè)智能化發(fā)展;加強產(chǎn)業(yè)協(xié)同監(jiān)管等措施。從企業(yè)方面,主要包括:調(diào)整產(chǎn)品結(jié)構(gòu),加強運營,提高獲利能力;加大研發(fā)投入力度,提高研發(fā)創(chuàng)新能力;重視發(fā)展中醫(yī)藥現(xiàn)代化;自建或合辦電商;向行業(yè)下游延伸等措施。
[Abstract]:The pharmaceutical manufacturing industry is not only related to the long-term development of the country and the life and health of the people, but also a knowledge-and technology-intensive high-tech industry, which is recognized as a "sunrise industry" by the world. From the perspective of social and livelihood development, The basic health conditions of the people, the quality of medicines, and the satisfaction of the medical and health care requirements all depend on the development of the pharmaceutical manufacturing industry. From the point of view of social and economic development, pharmaceutical manufacturing industry is not only the main component of the pharmaceutical industry, but also the organic component of our country's economy. Promoting the development of the pharmaceutical manufacturing industry can promote the employment of more people, import and export trade, as well as increased investment in infrastructure, technology, etc., thus promoting the economic development of the region and even the country. This paper studies the evaluation of the competitiveness of the regional pharmaceutical manufacturing industry in China, carries out a reasonable ranking, understands the current situation and influencing factors of the pharmaceutical manufacturing industry in Guangdong Province, and puts forward some reasonable suggestions for the development of the pharmaceutical manufacturing industry. This has a great influence on the promotion of the competitiveness of Guangdong pharmaceutical manufacturing industry. This paper based on the existing industrial competitiveness, pharmaceutical manufacturing industry and its competitiveness evaluation method related theory, In this paper, the competitiveness of pharmaceutical manufacturing industry in Guangdong Province is studied qualitatively and quantitatively. Firstly, the present situation of pharmaceutical manufacturing industry in China and Guangdong Province is analyzed. The contents mainly include the production and management of pharmaceutical manufacturing industry in China, the supporting policy and influence, and the industrial development and characteristics of pharmaceutical manufacturing industry in Guangdong Province. The evaluation system of regional competitiveness of pharmaceutical manufacturing industry is constructed objectively. Then, the raw data of pharmaceutical manufacturing related indexes in 27 provinces and cities of China from 2010 to 2014 are analyzed by factor analysis (Inner Mongolia, Tibet, Tibet, China). Through the empirical analysis of Qinghai and Ningxia), the conclusion is drawn that the comprehensive competitiveness of Guangdong pharmaceutical manufacturing industry is in the forefront through the comparison between Guangdong province and other provinces and cities, and the conclusion is: compared with other provinces and cities, the comprehensive competitiveness of Guangdong pharmaceutical manufacturing industry is in the forefront. With relatively large advantages, but there is still a big gap between the absolute advantage of provinces and cities. In addition, the development of related components is very uneven, investment efficiency and product innovation ability are only in the middle of the country. It is a serious obstacle to the healthy and sustainable development of the pharmaceutical manufacturing industry in Guangdong Province. Finally, according to the above conclusions, this paper puts forward some relevant countermeasures and suggestions for the future development of the pharmaceutical manufacturing industry in Guangdong Province from the two angles of the government and the enterprises. It mainly includes: vigorously developing the scale of pharmaceutical industry cluster, promoting regional coordinated development; optimizing industrial support mode and increasing capital input channels; expanding leading industrial enterprises, giving full play to regional pharmaceutical brand advantages; deepening foreign cooperation, Promote the intelligent development of industry, strengthen the industry coordination supervision and other measures. From the enterprise aspect, mainly include: adjust the product structure, strengthen the operation, improve the profit ability, increase the R & D investment, improve the R & D innovation ability; Attach importance to the development of modernization of Chinese medicine; self-establishment or co-operation of e-commerce; extension to the lower reaches of the industry and other measures.
【學(xué)位授予單位】：廣東藥科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：F426.72;F271

【參考文獻】

相關(guān)期刊論文 前10條

1 吳群紅;和沛森;高力軍;丁玎;郭夢童;宋健;李玲;;基于因子分析的公立醫(yī)院規(guī)制改革原因探究[J];中國衛(wèi)生經(jīng)濟;2014年09期

2 王玉芬;;江蘇新醫(yī)藥產(chǎn)業(yè)協(xié)同創(chuàng)新選擇[J];開放導(dǎo)報;2014年03期

3 周桐;尹文超;;山東省醫(yī)藥制造業(yè)的差異性影響因素[J];科技信息;2014年08期

4 賀加貝;符文奎;馮海;;臺州醫(yī)藥產(chǎn)業(yè)集群競爭力分析[J];經(jīng)濟論壇;2014年02期

5 賴俊明;;基于組織生態(tài)學(xué)的浙江醫(yī)藥產(chǎn)業(yè)發(fā)展對策[J];當(dāng)代經(jīng)濟;2014年01期

6 李飛群;;中國醫(yī)藥制造業(yè)現(xiàn)實競爭力的實證研究[J];科技情報開發(fā)與經(jīng)濟;2008年26期

7 趙玉林;邢光衛(wèi);;我國醫(yī)藥制造業(yè)區(qū)域競爭力評價[J];經(jīng)濟問題探索;2007年11期

8 曹軍偉;顧海;;基于偏離-份額法評價江蘇省醫(yī)藥制造業(yè)各子產(chǎn)業(yè)競爭力[J];中國藥房;2006年08期

9 金碚;高技術(shù)在中國產(chǎn)業(yè)發(fā)展中的地位和作用[J];中國工業(yè)經(jīng)濟;2003年12期

10 金碚;;經(jīng)濟學(xué)對競爭力的解釋[J];經(jīng)濟管理;2002年22期

相關(guān)博士學(xué)位論文 前1條

1 吳韶宸;江西醫(yī)藥產(chǎn)業(yè)競爭力研究[D];江西財經(jīng)大學(xué);2012年

相關(guān)碩士學(xué)位論文 前8條

1 熊名寧;貴州醫(yī)藥制造企業(yè)市場競爭力研究[D];貴州大學(xué);2014年

2 陳仕江;江西省醫(yī)藥制造業(yè)競爭力評價研究[D];南昌大學(xué);2014年

3 張曉鳳;基于模糊層次分析法的廣東省生物醫(yī)藥產(chǎn)業(yè)發(fā)展水平測評[D];華南理工大學(xué);2014年

4 墨瑋嬌;河北省醫(yī)藥制造業(yè)競爭力研究[D];河北經(jīng)貿(mào)大學(xué);2014年

5 石嶺;基于GEM模型的云南省生物醫(yī)藥產(chǎn)業(yè)集群競爭力研究[D];云南財經(jīng)大學(xué);2013年

6 孔偉;基于鉆石模型的我國醫(yī)藥產(chǎn)業(yè)競爭力研究[D];黑龍江大學(xué);2012年

7 龐立君;吉林省醫(yī)藥產(chǎn)業(yè)競爭力評價研究[D];吉林大學(xué);2009年

8 歐陽穎弋;廣東省醫(yī)藥產(chǎn)業(yè)可持續(xù)發(fā)展研究[D];暨南大學(xué);2006年

，

本文編號：1586259